Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment
Kashi Raj Bhattarai(Pharmaceutical Biotechnology (Czechia)), Daniel Savic(St. Jude Children's Research Hospital), Wenjian Yang(St. Jude Children's Research Hospital), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Brennan P. Bergeron(St. Jude Children's Research Hospital), Daniel C. Ferguson(University at Buffalo, State University of New York), Robert J. Mobley(St. Jude Children's Research Hospital), William E. Evans(St. Jude Children's Research Hospital), Sima Jeha(St. Jude Children's Research Hospital), Kelly R. Barnett(St. Jude Children's Research Hospital), Jonathan D. Diedrich(The Barbara Ann Karmanos Cancer Institute), Jun J. Yang(St. Jude Children's Research Hospital), Ching‐Hon Pui(American Cancer Society), Hiroto Inaba(St. Jude Children's Research Hospital), Elisabeth Paietta(Montefiore Medical Center), Kristine R. Crews(St. Jude Children's Research Hospital), Wendy Stock(University of Chicago), Cheng Cheng(St. Jude Children's Research Hospital), Mary V. Relling(St. Jude Children's Research Hospital)
Cited by 0
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k